Company intelligence / Profile preview

Celexion

Cambridge, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Celexion developed the SECANT yeast display platform for rapid, high-throughput discovery and engineering of human monoclonal antibodies against complex protein targets. Their assets and platform were acquired by Agenus in 2015 to integrate with additional antibody discovery technologies for immuno-oncology and infectious diseases. Celexion had at least one preclinical siRNA program targeting Nav1.5 for colorectal cancer.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodysiRNAProteinAntibody
Industry: Biotech

Beyond the preview

Go deeper on Celexion.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Celexion.

Explore the full profile